质氨酸从全身动脉释放出由内皮衍生的放松因子. 在肝素中和过程中,低血压的可能机制
P J Pearson1, P R Evora, K Ayrancioglu
1Cardiac Surgical Research, Mayo Clinic, Rochester, Minn 55905.
Circulation
|July 1, 1992
概括
用于逆转肝素的蛋白胺硫酸盐可以通过释放内皮衍生的放松因子 (EDRF) 来引起低血压. 这项研究证实,质胺刺激了动脉中的EDRF释放,解释了其血管扩张作用.
科学领域:
- 心血管药理学心血管药理学
- 内皮细胞功能 内皮细胞功能
背景情况:
- 胺硫酸盐用于逆转肝素的抗凝剂作用.
- 质氨酸的使用可能会导致低血压,可能与血管扩张有关.
- 质氨酸含有氨酸,是氧化 (NO) 的前体,是内皮衍生放松因子 (EDRF) 的活性成分.
研究的目的:
- 调查前胺是否刺激EDRF释放,导致血管扩张和低血压.
- 为了阐明原胺诱导的低血压背后的机制.
主要方法:
- 研究了带有内皮和没有内皮的狗动脉环 (冠状动脉,股骨,脏).
- 戒指被收缩并暴露在不断增加的质胺度中.
- 评估了NG-单甲基-L-氨酸 (L-NMMA),一种EDRF抑制剂和L-氨酸的作用.
主要成果:
- 在带内皮的动脉段中,原胺诱导了依赖度的放松.
- 这种放松明显大于没有内皮的部分.
- 由EDRF介导的放松被L-NMMA抑制,并被L-阿尔金因逆转.
结论:
- 质氨酸刺激EDRF从动脉内皮释放出来.
- 内皮依赖的血管扩张是原氨酸诱导的全身低血压的一个重要因素.
相关概念视频
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Vascular Spasm
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...


